Novo Nordisk A/S (NYSE:NVO) Upgraded to Buy at UBS Group
Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...
Alzheimer’s drugs eyed as next big obesity-like opportunity
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Novo Nordisk, Valo Health expand drug discovery collaboration
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug ...
Could Alzheimer’s treatment drugs be the next big investor opportunity after obesity pills?
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...
Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
UK Biotech Startup Takes Aim at Weight-Loss Leaders Novo, Lilly
A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...
13 Best Pharma Dividend Stocks To Buy In 2024
The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, ...
Taiwan News2d
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...
Mild Cognitive Impairment Market Is Predicted To Advance At A CAGR Of 11.6% By 2034 Delveinsight
The United States accounted for the highest market size of MCI, approximately 52% of the total market size in 7MM in 2023, in comparison to the other major markets, i.e., EU4 countries (Germany, ...
DelveInsight Business Research, LLP: Mild Cognitive Impairment Market is Predicted to Advance at a CAGR of 11.6% by 2034 | DelveInsight
According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...